Literature DB >> 14651728

An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

T Iwasa1, H Sano, A Sugiura, N Uchiyama, K Hara, H Okochi, K Nakagawa, T Yasumori, T Ishizaki.   

Abstract

AIMS: Monoamine oxidase (MAO) is located in human liver, and catalyses the oxidative deamination step of many xenobiotics. However, whether there exists an interethnic difference in MAO activities has, to our knowledge, not been clarified. We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.
METHODS: Oxidative deaminase activities were determined with the subcellular fractions of Japanese livers and the microsomal fraction of Caucasian livers using RIZ, 5-HT (MAO-A substrate) and 2-phenylethylamine (PEA) (MAO-B substrate) as substrates.
RESULTS: The oxidative deaminase activities of RIZ vs. 5-HT were highly (r = 0.87 and 0.96, P < 0.001) correlated with each other in both the microsomal and mitochondrial fractions of Japanese livers. Subsequent results were obtained from in vitro experiments using liver microsomes based upon these findings. The oxidative deaminase activities of RIZ were inhibited completely by the nanomolar-order concentration of clorgyline and Ro 41-1049 (MAO-A selective inhibitors), but not by that of Ro 16-6491 (MAO-B selective inhibitor). The majority of the mean Michaelis-Menten values for three substrates toward MAO obtained from six Japanese and six Caucasian liver microsomes reached no significant differences between the two ethnic groups. The mean microsomal oxidative deaminase activities assessed in 18 Japanese and 20 Caucasian livers using the three substrates also showed no significant differences between the two ethnic groups.
CONCLUSIONS: RIZ is mainly metabolized by MAO-A and the in vitro oxidative deaminase activities mediated via MAO-A and -B do not appear to differ between Japanese and Caucasians.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651728      PMCID: PMC1884399          DOI: 10.1046/j.1365-2125.2003.01922.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

Review 1.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa.

Authors:  J Balciuniene; A C Syvänen; H L McLeod; U Pettersson; E E Jazin
Journal:  J Mol Evol       Date:  2001-02       Impact factor: 2.395

3.  Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.

Authors:  K P Vyas; R A Halpin; L A Geer; J D Ellis; L Liu; H Cheng; C Chavez-Eng; B K Matuszewski; S L Varga; A R Guiblin; J D Rogers
Journal:  Drug Metab Dispos       Date:  2000-01       Impact factor: 3.922

4.  Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid.

Authors:  R M Geha; I Rebrin; K Chen; J C Shih
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

5.  Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.

Authors:  T Shimada; F Tsumura; H Yamazaki; F P Guengerich; K Inoue
Journal:  Pharmacogenetics       Date:  2001-03

Review 6.  Molecular characterization of monoamine oxidases A and B.

Authors:  C W Abell; S W Kwan
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

7.  Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.

Authors:  P Tfelt-Hansen; R E Ryan
Journal:  Neurology       Date:  2000       Impact factor: 9.910

Review 8.  The use of rizatriptan in the treatment of acute, multiple migraine attacks.

Authors:  J R Saper
Journal:  Neurology       Date:  2000       Impact factor: 9.910

9.  Rizatriptan versus usual care in long-term treatment of migraine.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000       Impact factor: 9.910

Review 10.  Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.

Authors:  P J Goadsby; R J Hargreaves
Journal:  Neurology       Date:  2000       Impact factor: 9.910

View more
  2 in total

1.  Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.

Authors:  Yusuke Masuo; Shushi Nagamori; Aoi Hasegawa; Kazuki Hayashi; Noriyoshi Isozumi; Noritaka Nakamichi; Yoshikatsu Kanai; Yukio Kato
Journal:  Pharm Res       Date:  2017-03-30       Impact factor: 4.200

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.